SCHEMBL25200734

SCHEMBL25200734

Cc1nc2ccc(-c3c[nH]c4nc(NCC5(F)CC5)ncc34)cc2s1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ DYRK2 Q92630 6/20 0.40
▸ BRD4 O60885 2/20 0.39
▸ CLK2 P49760 2/20 0.36
▸ CLK3 P49761 2/20 0.36
▸ DYRK1A Q13627 2/20 0.36
▸ ABL1 P00519 6/20 0.35
▸ MAPK1 P28482 1/20 0.34
▸ ACP1 P24666 1/20 0.34
▸ PCSK9 Q8NBP7 1/20 0.33
▸ KIT P10721 1/20 0.33
▸ PDGFRA P16234 1/20 0.33
▸ PIK3CD O00329 1/20 0.33
▸ PIP5K1C O60331 1/20 0.33
▸ PIK3CA P42336 1/20 0.33
▸ PIK3CB P42338 1/20 0.33
▸ PI4KA P42356 1/20 0.33
▸ PIK3CG P48736 1/20 0.33
▸ PI4KB Q9UBF8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30348393 1.00 DYRK2 (0.40) DYRK2BRD4CLK2CLK3DYRK1A
SCHEMBL25158435 0.96 DYRK2 (0.39) DYRK2BRD4CLK2CLK3DYRK1A
SCHEMBL30347846 0.96 DYRK2 (0.39) DYRK2BRD4CLK2CLK3DYRK1A
SCHEMBL30347206 0.95 DYRK2 (0.39) DYRK2BRD4CLK2CLK3DYRK1A
SCHEMBL25158122 0.95 DYRK2 (0.39) DYRK2BRD4CLK2CLK3DYRK1A
SCHEMBL25158024 0.90 BRD4 (0.40) DYRK2BRD4CLK2CLK3DYRK1A
SCHEMBL30348114 0.90 BRD4 (0.40) DYRK2BRD4CLK2CLK3DYRK1A
SCHEMBL25158026 0.88 BRD4 (0.38) DYRK2BRD4CLK2CLK3DYRK1A
SCHEMBL30347964 0.88 BRD4 (0.38) DYRK2BRD4CLK2CLK3DYRK1A
SCHEMBL30348819 0.85 BRD4 (0.43) DYRK2BRD4CLK2CLK3DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US disclosed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK2 3/4885BRD4 1417/4885CLK2 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback